Boston Scientific (NYSE:BSX) has closed on its previously announced a $1 billion debt offering.
The offering of 4.0% senior notes, which closed yesterday, is mostly earmarked for buying back some of the Marlborough, Mass.–based company’s other debt.
The notes are due March 2028 and are slated for the redemption of the remaining $600 million worth of the Marlborough, Mass.-based medical device company’s 2.65% notes due in October. The balance goes toward repayishort-term debt and toward paying related fees, expenses and premiums, the company said.
Boston Sci said earlier this month that an $861 million tax charge pushed it into the red during the fourth quarter and slashed full-year profits by 70%. The company nevertheless still managed to meet or beat the Street’s expectations.
